On Tuesday, Sequenom, Inc. (NASDAQ:SQNM)’s shares declined -4.65% to $2.05.
Sequenom, Inc. (SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, stated total revenues of $32.8 million for the second quarter of 2015, a decrease of 18% contrast to revenues of $39.8 million for the second quarter of 2014. Revenues for the second quarter of 2014 comprised of about $6.1 million of incremental “catch-up” payments from payors for services performed in preceding periods, in addition to the incremental change for the conversion from cash to accrual accounting for certain payors. No noteworthy catch-up collections were received in the second quarter of 2015, as the timeliness of collections has improved with additional payor contracts. Sequenom now has coverage for 172 million commercial lives and 40 million lives under Medicaid programs. The second quarter of 2015 had lower diagnostic services revenues contrast to the second quarter of 2014 by about $3 million, associated with the conversion of a referring laboratory partner to a patent pool licensee.
License revenues raised to $1.9 million for the second quarter of 2015, contrast to $0.4 million for the second quarter of 2014, reflecting the enhance in test fees under the Pooled Patents Agreement that was signed in December 2014.
Cash burn for the second quarter of 2015 was $2.9 million, contrast to $4.1 million in the same period of 2014. The second quarter 2015 cash burn excludes payment of costs related to the convertible debt exchange of $1.6 million. The loss from ongoing operations before income taxes reduced by 41% to $9.0 million for the second quarter of 2015 as contrast to $15.3 million for the second quarter of 2014.
Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women’s health and oncology markets in the United States and internationally. The company provides molecular based laboratory developed tests (LDTs) comprising MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; HerediT CF LDT, a carrier screen test to identify individuals with cystic fibrosis or genetic mutations; SensiGene fetal Rhesus D (RhD) LDT, a NIPT to determine the presence or absence of RhD factor by direct detection of the fetal RhD genotype in RhD negative mothers from a maternal blood sample; and VisibiliT LDT, a NIPT to detect fetal chromosomal abnormalities by determining the relative amount of chromosomal material present in circulating cell-free DNA in a maternal blood sample.
CIT Group Inc.(NYSE:CIT)’s shares dropped -3.22% to $42.04.
CIT Group Inc. (CIT) cit.com, a global leader in transportation finance, recently declared that CIT Maritime Finance offered a $61 million senior secured credit facility to Advantage Tankers, LLC, a Marshall Islands-based holding company established to acquire an operating fleet of crude tankers. The facility supports the acquisition of two Suezmax crude tankers which are employed on long-term charters to a multinational oil company. Financing was offered by CIT Bank, N.A., the principal bank partner of CIT. Terms of the transaction were not revealed.
CIT Group Inc. operates as the holding company for CIT bank that provides commercial financing and leasing products; and a suite of savings options in the United States. Its Transportation & International Finance segment offers leasing and financing solutions to operators and suppliers in the aviation and railcar industries.
At the end of Tuesday ‘s trade, Qunar Cayman Islands Ltd (NASDAQ:QUNR)‘s shares dipped -0.83% to $32.23.
Qunar Cayman Islands Limited (QUNR) declared that it has received the final judgment (the “Final Judgment”) from the Beijing High People’s Court (the “Court”) with respect to the contract dispute regarding an Inventory Distribution Agreement for hotels with eLong, Inc., which was formerly described in the Company’s annual report on Form 20-F for the fiscal year of 2014. The Company does not believe that the Final Judgment will have any material impact on its future business, results of operations or financial condition.
In the Final Judgment, the Court upheld the preceding judgment of the Beijing No. 1 Intermediate People’s Court from January 1, 2015 that (i) our partner, Beijing Qunar Software Technology Co., Ltd. (“Beijing Qunar”) shall credit to the advertisement account opened at Beijing Qunar by eLongNet Information Technology (Beijing) Co., Ltd. (“eLongNet”), a partner of eLong, Inc., the amount of RMB52,335,369 (about US$8.5 million) corresponding to the period up to September 30, 2014; and RMB36,450,000 (about US$6.0 million) for the period from October 1, 2014 through June 30, 2015; (ii) eLongNet shall pay Beijing Qunar a commission of RMB8,127,400 (about US$1.3 million) due under the Inventory Distribution Agreement; and (iii) the Inventory Distribution Agreement shall continue to be performed by both parties. The Court also ordered Beijing Qunar to pay eLongNet RMB227,599 (US$37 thousand) in legal fees, and apportioned court fees between the parties.
Qunar Cayman Islands Limited operates an online travel commerce platform in the People’s Republic of China. The company through its platform provides a range of travel products comprising flight tickets, hotels, vacation packages, and attraction tickets, in addition to display advertising, train tickets, car services, smart lodging, and other services. Its customers comprise flight travel service providers, airlines, independent hotels, online travel agencies, insurance service providers, and others.
UnitedHealth Group Inc (NYSE:UNH), ended its Tuesday ‘s trading session with 112.69% loss, and closed at $-2.60.
People enrolled in UnitedHealthcare’s Medicaid plan in Hawaii can now receive faster diagnosis and treatment of skin disorders using remote imaging and telemedicine technology.
Primary care physicians will be able to deliver more timely diagnosis and treatment through a new service that connects them to dermatologists online through a secure telemedicine application.
Using UnitedHealthcare’s new service, primary care physicians can capture digital images of the area of concern during the patient exam. They can then transmit the images to a dermatologist through a secure, online application using their computer, tablet or smartphone. This enables physicians to more quickly diagnose and treat skin disorders, benefiting patients – especially people who live in rural areas and lack access to dermatologists or other specialists. Patients can receive treatment faster, and save time and money.
UnitedHealth Group Incorporated operates as a diversified health and well-being company in the United States. The company’s UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; and health care coverage, and health and well-being services to individuals aged 50 and older addressing their needs for preventive and acute health care services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
